AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12480560 — intervention group
Group type: COMPARATOR
Intervention: Lactitol (60 g/day)
Number of subjects: 103
Study 10986366 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning count nouns
Number of subjects: 0
Study 10986366 — intervention group
Group type: COMPARATOR
Intervention: Learning facts
Number of subjects: 0
Study 9196611 — intervention group
Group type: COMPARATOR
Intervention: recombinant human GH (hGH) therapy
Number of subjects: 165
Study 1494071 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening (faecal occult blood screening)
Number of subjects: 140000
Study 29171135 — intervention group
Group type: EXPERIMENTAL
Intervention: ActivPals intervention
Number of subjects: 20
Study 29171135 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 28213841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 28213841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25512434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary sodium nitrite (10 mL, 1.8 μmol)
Number of subjects: 80
Study 25512434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary sodium nitrite (10 mL, 1.8 μmol) in a subgroup of 66 patients with thrombolysis in myocardial infarction ≤1 flow
Number of subjects: 80
Study 24413426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritive sucking stimulus (maternal breastfeeding)
Number of subjects: 64
Study 24413426 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking stimulus (researcher's little finger)
Number of subjects: 64
Study 24413426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesia stimulus)
Number of subjects: 64
Study 21396638 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional endoscopy
Number of subjects: 189
Study 21396638 — intervention group
Group type: EXPERIMENTAL
Intervention: Videocapsule endoscopy (VCE)
Number of subjects: 189
Study 21396638 — intervention group
Group type: COMPARATOR
Intervention: CT-enteroclysis
Number of subjects: 189
Study 18675877 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 688
Study 18675877 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 688
Study 18675877 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian typology
Number of subjects: 688
Study 16541115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil treatment
Number of subjects: 49
Study 16541115 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study 14647214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrothermally treated barley porridge (28 mg P as InsP(3)-InsP(6))
Number of subjects: 22
Study 14647214 — intervention group
Group type: COMPARATOR
Intervention: Control porridge (111 mg P as InsP(3)-InsP(6))
Number of subjects: 22
Study 14647214 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereals of malted barley (70 mg P as InsP(3)-InsP(6))
Number of subjects: 22
Study 14647214 — intervention group
Group type: COMPARATOR
Intervention: Flakes of barley (108 mg P as InsP(3)-InsP(6), no phytase activity)
Number of subjects: 22
Study 14647214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrothermally treated barley porridge
Number of subjects: 22
Study 14647214 — intervention group
Group type: COMPARATOR
Intervention: Control porridge
Number of subjects: 22
Study 14647214 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereals of malted barley
Number of subjects: 22
Study 14647214 — intervention group
Group type: COMPARATOR
Intervention: Flakes of barley
Number of subjects: 22
Study 10812819 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanvac-B (Group B; n = 59)
Number of subjects: 120
Study 10812819 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B (Group A; n = 61)
Number of subjects: 120
Study 8995025 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 0.5 i.u./kg/week
Number of subjects: 106
Study 8995025 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 1.0 i.u./kg/week
Number of subjects: 106
Study 1600704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 34
Study 4091239 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (loading dose of 1 mg/kg b.w. within 15 minutes followed by continuous infusion of 1 mg/kg b.w./h until the end of ECC)
Number of subjects: 506
Study 4091239 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without etomidate)
Number of subjects: 506
Study 4091239 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 506
Study 4091239 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study 31627337 — intervention group
Group type: EXPERIMENTAL
Intervention: CoMMIT program plus standard care
Number of subjects: 375
Study 31627337 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 375
Study 29464674 — intervention group
Group type: EXPERIMENTAL
Intervention: One-back task (secondary task)
Number of subjects: 0
Study 29464674 — intervention group
Group type: COMPARATOR
Intervention: Predictive learning task
Number of subjects: 0
Study 27348231 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea®), a loading dose of three monthly injections (2 mg/0.05 ml) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months
Number of subjects: 32
Study 27348231 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea®)
Number of subjects: 32
Study 24807339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 micrograms every 3 hours after 800 micrograms vaginal loading dose)
Number of subjects: 302
Study 24807339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 micrograms every 4 hours after 800 micrograms vaginal loading dose)
Number of subjects: 302
Study 24807339 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 micrograms every 3 hours after 800 micrograms vaginal loading dose)
Number of subjects: 302
Study 22229954 — intervention group
Group type: EXPERIMENTAL
Intervention: King Laryngeal Tube (KLT)
Number of subjects: 25
Study 22229954 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 25
Study 22229954 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 25
Study 20560409 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training (90-min sessions, twice a week for 12 weeks)
Number of subjects: 86
Study 20560409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study 20560409 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training
Number of subjects: 86
Study 16916339 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (100/50 microg)
Number of subjects: 14
Study 16916339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15315964 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD + RT (6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine followed by radiation therapy)
Number of subjects: 152
Study 15315964 — intervention group
Group type: COMPARATOR
Intervention: ABVD alone (6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 152
Study 15315964 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD + RT
Number of subjects: 152
Study 15315964 — intervention group
Group type: COMPARATOR
Intervention: ABVD alone
Number of subjects: 152
Study 10903600 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (propranolol)
Number of subjects: 119
Study 10903600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 119
Study 10903600 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group (portal blood flow-preserving procedures)
Number of subjects: 119
Study 10903600 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all three groups
Number of subjects: 119
Study 9291744 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine adrenaline tetracaine (LAT gel)
Number of subjects: 66
Study 9291744 — intervention group
Group type: COMPARATOR
Intervention: Injectable buffered lidocaine
Number of subjects: 66
Study 8318444 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock exposure during acquisition trials
Number of subjects: 60
Study 8318444 — intervention group
Group type: EXPERIMENTAL
Intervention: Startle reflex potentiation
Number of subjects: 60
Study 8318444 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance response
Number of subjects: 60
Study 8318444 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning course for startle reflex and skin conductance
Number of subjects: 60
Study 3518526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladosporium herbarum preparation
Number of subjects: 30
Study 3518526 — intervention group
Group type: COMPARATOR
Intervention: Histamine placebo
Number of subjects: 30
Study 29504488 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home remote activity monitoring (RAM) system
Number of subjects: 30
Study 30962230 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-choice multimodule stress management programme (intervention group A)
Number of subjects: 1080
Study 30962230 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet cognitive behavioural therapy (iCBT) fixed-order stress management (intervention group B)
Number of subjects: 1080
Study 30962230 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 1080
Study 27573387 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% trisodium citrate (TSC30%)
Number of subjects: 464
Study 26501683 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise testing
Number of subjects: 15
Study 26501683 — intervention group
Group type: COMPARATOR
Intervention: Cycle exercise testing
Number of subjects: 15
Study 22874091 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior‐posterior upper cervical mobilization (APUCM)
Number of subjects: 32
Study 22874091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21338801 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine somatotropin (bST) treatment
Number of subjects: 32
Study 21338801 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced lactation (estradiol-17β and progesterone)
Number of subjects: 32
Study 21338801 — intervention group
Group type: COMPARATOR
Intervention: Induced lactation
Number of subjects: 32
Study 18397338 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study 18397338 — intervention group
Group type: EXPERIMENTAL
Intervention: CACE estimators using multiple imputation methods
Number of subjects: 0
Study 17267589 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 49
Study 15839861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceridal lipolotion instilled in the ear canal with a syringe once a week for 12 months
Number of subjects: 39
Study 15839861 — intervention group
Group type: COMPARATOR
Intervention: No intervention (earwax removal only)
Number of subjects: 39
Study 12161767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 158
Study 12161767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 10218362 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment (2 ml, three times a day for three days)
Number of subjects: 48
Study 10218362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7838039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/doxorubicin (Cy/A)
Number of subjects: 134
Study 7838039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/teniposide (P1/VM)
Number of subjects: 134
Study 7838039 — intervention group
Group type: COMPARATOR
Intervention: Event free survival
Number of subjects: 134
Study 7838039 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 134
Study 2141743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen as a supplement to conservative treatment
Number of subjects: 42
Study 2141743 — intervention group
Group type: COMPARATOR
Intervention: Placebo as a supplement to conservative treatment
Number of subjects: 42
Study 158003 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder face mask with 1.19% clindamycin phosphate in 70% ethanol applied once daily for 5 days
Number of subjects: 29
Study 158003 — intervention group
Group type: COMPARATOR
Intervention: Solution with 1.19% clindamycin phosphate in 70% ethanol applied once daily for 5 days
Number of subjects: 29
Study 158003 — intervention group
Group type: COMPARATOR
Intervention: Powder face mask without clindamycin phosphate applied once daily for 5 days
Number of subjects: 29
Study 31350270 — intervention group
Group type: EXPERIMENTAL
Intervention: peficitinib 100 mg once daily
Number of subjects: 507
Study 31350270 — intervention group
Group type: EXPERIMENTAL
Intervention: peficitinib 150 mg once daily
Number of subjects: 507
Study 31350270 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 507
Study 28683231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound-intensity feedback during running
Number of subjects: 14
Study 26044715 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn Infection Control and Care Initiative (NICCI) intervention, which includes infection control in health facilities, promoting infection prevention practices, and improving referral timeliness.
Number of subjects: 0
Study 26044715 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 23504137 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐modality adjuvant therapy
Number of subjects: 180
Study 23504137 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐modality adjuvant therapy
Number of subjects: 180
Study 23504137 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery only
Number of subjects: 180
Study 23504137 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (non‐cancer group)
Number of subjects: 180
Study 21503263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (a once‐daily inhaled anticholinergic)
Number of subjects: 0
Study 19364166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 240 mg x d(‐1)
Number of subjects: 77
Study 19364166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 77
Study 19364166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 16765287 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative women with HIV-positive partners
Number of subjects: 349
Study 16765287 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants with HIV-positive partners
Number of subjects: 349
Study 16765287 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative women
Number of subjects: 349
Study 14657447 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic treatment
Number of subjects: 58
Study 14657447 — intervention group
Group type: COMPARATOR
Intervention: Phonological treatment
Number of subjects: 58
Study 14657447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 11521809 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus radiotherapy (299 patients)
Number of subjects: 579
Study 11521809 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (280 patients)
Number of subjects: 579
Study 11521809 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus radiotherapy
Number of subjects: 579
Study 9988898 — intervention group
Group type: EXPERIMENTAL
Intervention: AMO 2 x 1000 mg/day (group A)
Number of subjects: 100
Study 9988898 — intervention group
Group type: EXPERIMENTAL
Intervention: ACA 2 x 1250 mg/day (group B)
Number of subjects: 100
Study 9988898 — intervention group
Group type: EXPERIMENTAL
Intervention: OME + AZI treatment
Number of subjects: 100
Study 9988898 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 100
Study 7816518 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct biochemical analysis of chorionic villus biopsies
Number of subjects: 7
Study 2718921 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet providing 1 g ascorbic acid/d
Number of subjects: 0
Study 2718921 — intervention group
Group type: COMPARATOR
Intervention: Diet limiting ascorbic acid to about 20 mg/d
Number of subjects: 0
Study 956519 — intervention group
Group type: EXPERIMENTAL
Intervention: Full view photographic slides
Number of subjects: 30
Study 956519 — intervention group
Group type: COMPARATOR
Intervention: Portrait view slides
Number of subjects: 30
Study 30411201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the medial PFC
Number of subjects: 100
Study 30411201 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 100
Study 30411201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 100
Study 28991332 — intervention group
Group type: EXPERIMENTAL
Intervention: AT LISA tri group (32 eyes)
Number of subjects: 52
Study 28991332 — intervention group
Group type: COMPARATOR
Intervention: AT LISA group (38 eyes)
Number of subjects: 52
Study 28991332 — intervention group
Group type: COMPARATOR
Intervention: ReSTOR group (34 eyes)
Number of subjects: 52
Study 28991332 — intervention group
Group type: COMPARATOR
Intervention: Trifocal and bifocal groups
Number of subjects: 52
Study 25969531 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of antituberculosis therapy using intermittent directly observed therapy (DOTs)
Number of subjects: 197
Study 25969531 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 months of antituberculosis therapy using intermittent directly observed therapy (DOTs)
Number of subjects: 197
Study 23342782 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic acupuncture
Number of subjects: 189
Study 23342782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton moxibustion
Number of subjects: 189
Study 23342782 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle
Number of subjects: 189
Study 23342782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapping‐cupping
Number of subjects: 189
Study 23342782 — intervention group
Group type: COMPARATOR
Intervention: Medication (Valaciclovir Hydrochlordide and vitamin B1)
Number of subjects: 189
Study 20891044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernilton (two doses, specific dosages not mentioned)
Number of subjects: 0
Study 18558274 — intervention group
Group type: EXPERIMENTAL
Intervention: C7‐T1 manipulation on the dominant side
Number of subjects: 30
Study 18558274 — intervention group
Group type: EXPERIMENTAL
Intervention: C7‐T1 manipulation on the nondominant side
Number of subjects: 30
Study 18558274 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham‐manual procedure)
Number of subjects: 30
Study 15857084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic bactericidal curettage (UBC) with an ultrasonic scaler
Number of subjects: 33
Study 15857084 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instrumentation
Number of subjects: 33
Study 15857084 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment after hand instrumentation
Number of subjects: 33
Study 11973484 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-DTPA aerosol inhalation scintigraphy
Number of subjects: 26
Study 11973484 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 11973484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (PFT)
Number of subjects: 26
Study 10714276 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 39
Study 10714276 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 39
Study 10714276 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-bypass levels)
Number of subjects: 39
Study 8562664 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intravenous clomipramine infusion
Number of subjects: 28
Study 8562664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral clomipramine treatment
Number of subjects: 28
Study 8562664 — intervention group
Group type: COMPARATOR
Intervention: Patients who worsened after clomipramine infusion
Number of subjects: 28
Study 1669517 — intervention group
Group type: COMPARATOR
Intervention: Decreased caloric intake alone
Number of subjects: 872
Study 1669517 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise
Number of subjects: 872
Study 1669517 — intervention group
Group type: COMPARATOR
Intervention: Limiting caloric intake
Number of subjects: 872
Study 1669517 — intervention group
Group type: COMPARATOR
Intervention: Multifactor intervention (weight reduction, sodium and alcohol intake reduction, increased physical activity)
Number of subjects: 872
Study 6762807 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 11
Study 6762807 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 11
Study 31585544 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO group (asthma treatment guided by FENO plus symptoms)
Number of subjects: 100
Study 31585544 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (asthma treatment guided by symptoms only)
Number of subjects: 100
Study 31585544 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO group
Number of subjects: 100
Study 27589252 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 435
Study 25524401 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 74
Study 25524401 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 74
Study 23283828 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair removal prior to ear surgery
Number of subjects: 136
Study 23283828 — intervention group
Group type: COMPARATOR
Intervention: No hair removal prior to ear surgery
Number of subjects: 136
Study 22800982 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory (BPI)
Number of subjects: 274
Study 22800982 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG (3-item abbreviated version of BPI)
Number of subjects: 274
Study 22800982 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 pain scale
Number of subjects: 274